Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Andrew E. Mulberg, Christina Bucci-Rechtweg, Joseph Giuliano, David Jacoby, Franklin K. Johnson, Qing Liu, Deborah Marsden, Scott McGoohan, Robert Nelson, Nita Patel, Klaus Romero, Vikram Sinha, Sheela Sitaraman, John Spaltro, Vivian Kessler

ABSTRACT

Rare or orphan diseases often are inherited and overwhelmingly affect children. Many of these diseases have no treatments, are incurable, and have a devastating impact on patients and their families. Regulatory standards for drug approval for rare diseases must ensure that patients receive safe and efficacious treatments. However, regulatory bodies have shown flexibility in applying these standards to drug development in rare diseases, given the unique challenges that hinder efficient and effective traditional clinical trials, including low patient numbers, limited understanding of disease pathology and progression, variability in disease presentation, and a lack of established endpoints.To take steps toward improving rare disease clinical development strategies under current global regulatory statutes, Amicus Therapeutics, Inc. and BioNJ convened a 1-day meeting that included representatives from the Food and Drug Administration (FDA), biopharmaceutical industry, and not-for-profit agencies. The meeting focused on orphan diseases in pediatric and adult patients and was intended to identify potential strategies to overcome regulatory hurdles through open collaboration.During this meeting, several strategies were identified to minimize the limitations associated with low patient numbers in rare diseases, including the use of natural history to generate historical control data in comparisons, simulations, and identifying inclusion/exclusion criteria and appropriate endpoints. Novel approaches to clinical trial design were discussed to minimize patient exposure to placebo and to reduce the numbers of patients and clinical trials needed for providing substantial evidence. Novel statistical analysis approaches were also discussed to address the inherent challenges of small patient numbers. Areas of urgent unmet need were identified, including the need to develop registries that protect patient identities, to establish close collaboration and communication between the sponsor and regulatory bodies to address methodological and statistical challenges, to collaborate in pre-competitive opportunities within multiple sponsors and in conjunction with academia and disease-specific patient advocacy groups for optimal data sharing, and to develop harmonized guidelines for data extrapolation from source to target pediatric populations. Ultimately, these innovations will help in solving many regulatory challenges in rare disease drug development and encourage the availability of new treatments for patients with rare diseases. More... »

PAGES

36

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13023-019-1017-5

DOI

http://dx.doi.org/10.1186/s13023-019-1017-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112023566

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30736861


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0104", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Statistics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/01", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Mathematical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mulberg", 
        "givenName": "Andrew E.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, One Health Plaza, 07936, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bucci-Rechtweg", 
        "givenName": "Christina", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giuliano", 
        "givenName": "Joseph", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BioMarin (United States)", 
          "id": "https://www.grid.ac/institutes/grid.422932.c", 
          "name": [
            "BioMarin Pharmaceutical Inc., 770 Lindaro St, 94901, San Rafael, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacoby", 
        "givenName": "David", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnson", 
        "givenName": "Franklin K.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Qing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ultragenyx Pharmaceutical (United States)", 
          "id": "https://www.grid.ac/institutes/grid.430528.8", 
          "name": [
            "Ultragenyx Pharmaceutical, Inc., 60 Leveroni Ct, 94949, Novato, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marsden", 
        "givenName": "Deborah", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vertex Pharmaceuticals (United States)", 
          "id": "https://www.grid.ac/institutes/grid.422219.e", 
          "name": [
            "Vertex Pharmaceuticals, 50 Northern Ave, 02210, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McGoohan", 
        "givenName": "Scott", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johnson & Johnson (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417429.d", 
          "name": [
            "Johnson & Johnson, 920 Route 202 South, 08869, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nelson", 
        "givenName": "Robert", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Nita", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Critical Path Institute", 
          "id": "https://www.grid.ac/institutes/grid.417621.7", 
          "name": [
            "Critical Path Institute, 1730 East River Rd, 85718, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Romero", 
        "givenName": "Klaus", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co, Inc. 351 North Sumneytown Pike, 19454, North Wales, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sinha", 
        "givenName": "Vikram", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sitaraman", 
        "givenName": "Sheela", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spaltro", 
        "givenName": "John", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amicus Therapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427771.0", 
          "name": [
            "Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kessler", 
        "givenName": "Vivian", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.jval.2014.08.2672", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001374845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10928-014-9390-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021206364", 
          "https://doi.org/10.1007/s10928-014-9390-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1542/peds.2010-3487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030501712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt.415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042418314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-016-0464-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045472021", 
          "https://doi.org/10.1186/s13023-016-0464-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-016-0464-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045472021", 
          "https://doi.org/10.1186/s13023-016-0464-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2168479015580383", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046044704"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2168479015580383", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046044704"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-014-0195-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048681780", 
          "https://doi.org/10.1186/s13023-014-0195-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-014-0195-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048681780", 
          "https://doi.org/10.1186/s13023-014-0195-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2009.03484.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049797936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2009.03484.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049797936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ejhg.2016.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051868457", 
          "https://doi.org/10.1038/ejhg.2016.30"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2014.08.1963", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052978872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bcp.13331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086350396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2017.05.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090667239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13063-017-2099-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090935031", 
          "https://doi.org/10.1186/s13063-017-2099-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13063-017-2099-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090935031", 
          "https://doi.org/10.1186/s13063-017-2099-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajmg.a.38413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091222876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajmg.a.38413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091222876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2168479017725558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091274867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2168479017725558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091274867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-319-67144-4_1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099613491", 
          "https://doi.org/10.1007/978-3-319-67144-4_1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajmg.a.38629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100921774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajmg.a.38629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100921774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.k698", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101383739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pst.1862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103442176"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1712649", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103628705"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13063-018-2645-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104168583", 
          "https://doi.org/10.1186/s13063-018-2645-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13063-018-2645-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104168583", 
          "https://doi.org/10.1186/s13063-018-2645-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/psp4.12304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104889424"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2352-4642(18)30179-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105264142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2352-4642(18)30179-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105264142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2018.10136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106130170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-018-0836-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106678996", 
          "https://doi.org/10.1186/s13023-018-0836-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-018-0836-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106678996", 
          "https://doi.org/10.1186/s13023-018-0836-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-018-0836-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106678996", 
          "https://doi.org/10.1186/s13023-018-0836-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "Rare or orphan diseases often are inherited and overwhelmingly affect children. Many of these diseases have no treatments, are incurable, and have a devastating impact on patients and their families. Regulatory standards for drug approval for rare diseases must ensure that patients receive safe and efficacious treatments. However, regulatory bodies have shown flexibility in applying these standards to drug development in rare diseases, given the unique challenges that hinder efficient and effective traditional clinical trials, including low patient numbers, limited understanding of disease pathology and progression, variability in disease presentation, and a lack of established endpoints.To take steps toward improving rare disease clinical development strategies under current global regulatory statutes, Amicus Therapeutics, Inc. and BioNJ convened a 1-day meeting that included representatives from the Food and Drug Administration (FDA), biopharmaceutical industry, and not-for-profit agencies. The meeting focused on orphan diseases in pediatric and adult patients and was intended to identify potential strategies to overcome regulatory hurdles through open collaboration.During this meeting, several strategies were identified to minimize the limitations associated with low patient numbers in rare diseases, including the use of natural history to generate historical control data in comparisons, simulations, and identifying inclusion/exclusion criteria and appropriate endpoints. Novel approaches to clinical trial design were discussed to minimize patient exposure to placebo and to reduce the numbers of patients and clinical trials needed for providing substantial evidence. Novel statistical analysis approaches were also discussed to address the inherent challenges of small patient numbers. Areas of urgent unmet need were identified, including the need to develop registries that protect patient identities, to establish close collaboration and communication between the sponsor and regulatory bodies to address methodological and statistical challenges, to collaborate in pre-competitive opportunities within multiple sponsors and in conjunction with academia and disease-specific patient advocacy groups for optimal data sharing, and to develop harmonized guidelines for data extrapolation from source to target pediatric populations. Ultimately, these innovations will help in solving many regulatory challenges in rare disease drug development and encourage the availability of new treatments for patients with rare diseases.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13023-019-1017-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1036535", 
        "issn": [
          "1750-1172"
        ], 
        "name": "Orphanet Journal of Rare Diseases", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders", 
    "pagination": "36", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "984faac0d80d2746bbaeb1fbfcf11a848ea5b1c176b6ca0308a67249da679a2e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30736861"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101266602"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13023-019-1017-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112023566"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13023-019-1017-5", 
      "https://app.dimensions.ai/details/publication/pub.1112023566"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89826_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13023-019-1017-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13023-019-1017-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13023-019-1017-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13023-019-1017-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13023-019-1017-5'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      54 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13023-019-1017-5 schema:about anzsrc-for:01
2 anzsrc-for:0104
3 schema:author N79d2953b871347f5a241ce10e333f5c4
4 schema:citation sg:pub.10.1007/978-3-319-67144-4_1
5 sg:pub.10.1007/s10928-014-9390-0
6 sg:pub.10.1038/ejhg.2016.30
7 sg:pub.10.1186/s13023-014-0195-4
8 sg:pub.10.1186/s13023-016-0464-5
9 sg:pub.10.1186/s13023-018-0836-0
10 sg:pub.10.1186/s13063-017-2099-9
11 sg:pub.10.1186/s13063-018-2645-0
12 https://doi.org/10.1001/jama.2018.10136
13 https://doi.org/10.1002/ajmg.a.38413
14 https://doi.org/10.1002/ajmg.a.38629
15 https://doi.org/10.1002/cpt.415
16 https://doi.org/10.1002/psp4.12304
17 https://doi.org/10.1002/pst.1862
18 https://doi.org/10.1016/j.jval.2014.08.1963
19 https://doi.org/10.1016/j.jval.2014.08.2672
20 https://doi.org/10.1016/j.jval.2017.05.015
21 https://doi.org/10.1016/s2352-4642(18)30179-2
22 https://doi.org/10.1056/nejmoa1712649
23 https://doi.org/10.1111/bcp.13331
24 https://doi.org/10.1111/j.1365-2125.2009.03484.x
25 https://doi.org/10.1136/bmj.k698
26 https://doi.org/10.1177/2168479015580383
27 https://doi.org/10.1177/2168479017725558
28 https://doi.org/10.1542/peds.2010-3487
29 schema:datePublished 2019-12
30 schema:datePublishedReg 2019-12-01
31 schema:description Rare or orphan diseases often are inherited and overwhelmingly affect children. Many of these diseases have no treatments, are incurable, and have a devastating impact on patients and their families. Regulatory standards for drug approval for rare diseases must ensure that patients receive safe and efficacious treatments. However, regulatory bodies have shown flexibility in applying these standards to drug development in rare diseases, given the unique challenges that hinder efficient and effective traditional clinical trials, including low patient numbers, limited understanding of disease pathology and progression, variability in disease presentation, and a lack of established endpoints.To take steps toward improving rare disease clinical development strategies under current global regulatory statutes, Amicus Therapeutics, Inc. and BioNJ convened a 1-day meeting that included representatives from the Food and Drug Administration (FDA), biopharmaceutical industry, and not-for-profit agencies. The meeting focused on orphan diseases in pediatric and adult patients and was intended to identify potential strategies to overcome regulatory hurdles through open collaboration.During this meeting, several strategies were identified to minimize the limitations associated with low patient numbers in rare diseases, including the use of natural history to generate historical control data in comparisons, simulations, and identifying inclusion/exclusion criteria and appropriate endpoints. Novel approaches to clinical trial design were discussed to minimize patient exposure to placebo and to reduce the numbers of patients and clinical trials needed for providing substantial evidence. Novel statistical analysis approaches were also discussed to address the inherent challenges of small patient numbers. Areas of urgent unmet need were identified, including the need to develop registries that protect patient identities, to establish close collaboration and communication between the sponsor and regulatory bodies to address methodological and statistical challenges, to collaborate in pre-competitive opportunities within multiple sponsors and in conjunction with academia and disease-specific patient advocacy groups for optimal data sharing, and to develop harmonized guidelines for data extrapolation from source to target pediatric populations. Ultimately, these innovations will help in solving many regulatory challenges in rare disease drug development and encourage the availability of new treatments for patients with rare diseases.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N159f3851ce974435911e6a11b69340ba
36 Ncb9a139099764aebb7b711ed384e22a7
37 sg:journal.1036535
38 schema:name Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
39 schema:pagination 36
40 schema:productId N07d15ef9e59d4466be42a771739e81f2
41 N2403ec5cce24411c87120fe6acccb175
42 N2582818a15954be395c4782dd7b211d7
43 N77b02b24a0594d6e929d8076592f5d4c
44 Na4e2f491a68346ac8afb5a6850bb2fc6
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112023566
46 https://doi.org/10.1186/s13023-019-1017-5
47 schema:sdDatePublished 2019-04-11T10:04
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Nd7b0b827cfea4a52a44738551ad8e14d
50 schema:url https://link.springer.com/10.1186%2Fs13023-019-1017-5
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N00048c917b344354b6864d0f2c4f7820 rdf:first N9f64bbc8ccdb43b5bad29c893294dfa1
55 rdf:rest N6b8d96d3e3e64f46bbc0c42f490c3df6
56 N07d15ef9e59d4466be42a771739e81f2 schema:name pubmed_id
57 schema:value 30736861
58 rdf:type schema:PropertyValue
59 N087e9c2d9276436c961bcbe991320176 rdf:first N7fdb3c586acb4617a550c13548e47519
60 rdf:rest N00048c917b344354b6864d0f2c4f7820
61 N0b82167e95644abfb6d2685eeb950bb8 schema:affiliation https://www.grid.ac/institutes/grid.427771.0
62 schema:familyName Mulberg
63 schema:givenName Andrew E.
64 rdf:type schema:Person
65 N0c0429cb8ca041c9895f128448dc0836 schema:affiliation https://www.grid.ac/institutes/grid.422219.e
66 schema:familyName McGoohan
67 schema:givenName Scott
68 rdf:type schema:Person
69 N0f8fa016878048c2b0f7d763e4ad76e0 rdf:first N7676bba2cbdb49c58386d0322fef09cf
70 rdf:rest rdf:nil
71 N14e9ee9fa67f44f6baafc4464ef3fd56 schema:affiliation https://www.grid.ac/institutes/grid.427771.0
72 schema:familyName Sitaraman
73 schema:givenName Sheela
74 rdf:type schema:Person
75 N159f3851ce974435911e6a11b69340ba schema:volumeNumber 14
76 rdf:type schema:PublicationVolume
77 N19df6163848e4a4fa3a9f93d493ddd50 schema:affiliation https://www.grid.ac/institutes/grid.417621.7
78 schema:familyName Romero
79 schema:givenName Klaus
80 rdf:type schema:Person
81 N2403ec5cce24411c87120fe6acccb175 schema:name readcube_id
82 schema:value 984faac0d80d2746bbaeb1fbfcf11a848ea5b1c176b6ca0308a67249da679a2e
83 rdf:type schema:PropertyValue
84 N2582818a15954be395c4782dd7b211d7 schema:name nlm_unique_id
85 schema:value 101266602
86 rdf:type schema:PropertyValue
87 N290adedc81414416b207a391e0eb656c schema:affiliation https://www.grid.ac/institutes/grid.417429.d
88 schema:familyName Nelson
89 schema:givenName Robert
90 rdf:type schema:Person
91 N2ca7c3f967fd46e3af83c25a7ba16182 schema:affiliation https://www.grid.ac/institutes/grid.427771.0
92 schema:familyName Johnson
93 schema:givenName Franklin K.
94 rdf:type schema:Person
95 N368ef6d24bf64c34abeb116ebded5190 rdf:first N19df6163848e4a4fa3a9f93d493ddd50
96 rdf:rest N84024ff26f8b437dbd26320f015521cf
97 N3ab9bb51e391434fb5fe30d3307bd45f schema:affiliation https://www.grid.ac/institutes/grid.417993.1
98 schema:familyName Sinha
99 schema:givenName Vikram
100 rdf:type schema:Person
101 N456b4229dfe9476fb8586b7421453c83 rdf:first Naa23ee66e65e4414b7e7abac0732464d
102 rdf:rest Nc453827796544c57a07100b2c90a1e2e
103 N6b8d96d3e3e64f46bbc0c42f490c3df6 rdf:first N0c0429cb8ca041c9895f128448dc0836
104 rdf:rest Nb3edd8c87d73455fb1a5c1e77d14dd07
105 N7676bba2cbdb49c58386d0322fef09cf schema:affiliation https://www.grid.ac/institutes/grid.427771.0
106 schema:familyName Kessler
107 schema:givenName Vivian
108 rdf:type schema:Person
109 N77b02b24a0594d6e929d8076592f5d4c schema:name doi
110 schema:value 10.1186/s13023-019-1017-5
111 rdf:type schema:PropertyValue
112 N79d2953b871347f5a241ce10e333f5c4 rdf:first N0b82167e95644abfb6d2685eeb950bb8
113 rdf:rest Nb9d2301d9c364057bde7aa04555290c1
114 N7fdb3c586acb4617a550c13548e47519 schema:affiliation https://www.grid.ac/institutes/grid.427771.0
115 schema:familyName Liu
116 schema:givenName Qing
117 rdf:type schema:Person
118 N84024ff26f8b437dbd26320f015521cf rdf:first N3ab9bb51e391434fb5fe30d3307bd45f
119 rdf:rest N8405dbf4079f48b4bc5109c003b524fb
120 N8405dbf4079f48b4bc5109c003b524fb rdf:first N14e9ee9fa67f44f6baafc4464ef3fd56
121 rdf:rest Ndd43d38a20f34db994e2ad695c2a6321
122 N87e3e4388c874b9aa0e8cf2798227e98 rdf:first Nb69937a3423e4eb3931d6602770e8b46
123 rdf:rest N368ef6d24bf64c34abeb116ebded5190
124 N9f64bbc8ccdb43b5bad29c893294dfa1 schema:affiliation https://www.grid.ac/institutes/grid.430528.8
125 schema:familyName Marsden
126 schema:givenName Deborah
127 rdf:type schema:Person
128 Na4e2f491a68346ac8afb5a6850bb2fc6 schema:name dimensions_id
129 schema:value pub.1112023566
130 rdf:type schema:PropertyValue
131 Na87ac343152b4496a2f92d46b42264e9 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
132 schema:familyName Bucci-Rechtweg
133 schema:givenName Christina
134 rdf:type schema:Person
135 Na8dbd4fdf4074d61b59913fbd31a2dc7 rdf:first Naaad26e0766247f3948f2808c3029ae4
136 rdf:rest N456b4229dfe9476fb8586b7421453c83
137 Naa23ee66e65e4414b7e7abac0732464d schema:affiliation https://www.grid.ac/institutes/grid.422932.c
138 schema:familyName Jacoby
139 schema:givenName David
140 rdf:type schema:Person
141 Naaad26e0766247f3948f2808c3029ae4 schema:affiliation https://www.grid.ac/institutes/grid.427771.0
142 schema:familyName Giuliano
143 schema:givenName Joseph
144 rdf:type schema:Person
145 Nb3edd8c87d73455fb1a5c1e77d14dd07 rdf:first N290adedc81414416b207a391e0eb656c
146 rdf:rest N87e3e4388c874b9aa0e8cf2798227e98
147 Nb69937a3423e4eb3931d6602770e8b46 schema:affiliation https://www.grid.ac/institutes/grid.427771.0
148 schema:familyName Patel
149 schema:givenName Nita
150 rdf:type schema:Person
151 Nb9d2301d9c364057bde7aa04555290c1 rdf:first Na87ac343152b4496a2f92d46b42264e9
152 rdf:rest Na8dbd4fdf4074d61b59913fbd31a2dc7
153 Nc453827796544c57a07100b2c90a1e2e rdf:first N2ca7c3f967fd46e3af83c25a7ba16182
154 rdf:rest N087e9c2d9276436c961bcbe991320176
155 Ncb9a139099764aebb7b711ed384e22a7 schema:issueNumber 1
156 rdf:type schema:PublicationIssue
157 Nd793f869c1d64f48ad4e0dd68f621543 schema:affiliation https://www.grid.ac/institutes/grid.427771.0
158 schema:familyName Spaltro
159 schema:givenName John
160 rdf:type schema:Person
161 Nd7b0b827cfea4a52a44738551ad8e14d schema:name Springer Nature - SN SciGraph project
162 rdf:type schema:Organization
163 Ndd43d38a20f34db994e2ad695c2a6321 rdf:first Nd793f869c1d64f48ad4e0dd68f621543
164 rdf:rest N0f8fa016878048c2b0f7d763e4ad76e0
165 anzsrc-for:01 schema:inDefinedTermSet anzsrc-for:
166 schema:name Mathematical Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:0104 schema:inDefinedTermSet anzsrc-for:
169 schema:name Statistics
170 rdf:type schema:DefinedTerm
171 sg:journal.1036535 schema:issn 1750-1172
172 schema:name Orphanet Journal of Rare Diseases
173 rdf:type schema:Periodical
174 sg:pub.10.1007/978-3-319-67144-4_1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099613491
175 https://doi.org/10.1007/978-3-319-67144-4_1
176 rdf:type schema:CreativeWork
177 sg:pub.10.1007/s10928-014-9390-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021206364
178 https://doi.org/10.1007/s10928-014-9390-0
179 rdf:type schema:CreativeWork
180 sg:pub.10.1038/ejhg.2016.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051868457
181 https://doi.org/10.1038/ejhg.2016.30
182 rdf:type schema:CreativeWork
183 sg:pub.10.1186/s13023-014-0195-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048681780
184 https://doi.org/10.1186/s13023-014-0195-4
185 rdf:type schema:CreativeWork
186 sg:pub.10.1186/s13023-016-0464-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045472021
187 https://doi.org/10.1186/s13023-016-0464-5
188 rdf:type schema:CreativeWork
189 sg:pub.10.1186/s13023-018-0836-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106678996
190 https://doi.org/10.1186/s13023-018-0836-0
191 rdf:type schema:CreativeWork
192 sg:pub.10.1186/s13063-017-2099-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090935031
193 https://doi.org/10.1186/s13063-017-2099-9
194 rdf:type schema:CreativeWork
195 sg:pub.10.1186/s13063-018-2645-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104168583
196 https://doi.org/10.1186/s13063-018-2645-0
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1001/jama.2018.10136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106130170
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1002/ajmg.a.38413 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091222876
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1002/ajmg.a.38629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100921774
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1002/cpt.415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042418314
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1002/psp4.12304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104889424
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1002/pst.1862 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103442176
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/j.jval.2014.08.1963 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052978872
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1016/j.jval.2014.08.2672 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001374845
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/j.jval.2017.05.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090667239
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/s2352-4642(18)30179-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105264142
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1056/nejmoa1712649 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103628705
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1111/bcp.13331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086350396
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1111/j.1365-2125.2009.03484.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049797936
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1136/bmj.k698 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101383739
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1177/2168479015580383 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046044704
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1177/2168479017725558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091274867
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1542/peds.2010-3487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030501712
231 rdf:type schema:CreativeWork
232 https://www.grid.ac/institutes/grid.417429.d schema:alternateName Johnson & Johnson (United States)
233 schema:name Johnson & Johnson, 920 Route 202 South, 08869, Raritan, NJ, USA
234 rdf:type schema:Organization
235 https://www.grid.ac/institutes/grid.417621.7 schema:alternateName Critical Path Institute
236 schema:name Critical Path Institute, 1730 East River Rd, 85718, Tucson, AZ, USA
237 rdf:type schema:Organization
238 https://www.grid.ac/institutes/grid.417993.1 schema:alternateName MSD (United States)
239 schema:name Merck & Co, Inc. 351 North Sumneytown Pike, 19454, North Wales, PA, USA
240 rdf:type schema:Organization
241 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
242 schema:name Novartis Pharmaceuticals Corporation, One Health Plaza, 07936, East Hanover, NJ, USA
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.422219.e schema:alternateName Vertex Pharmaceuticals (United States)
245 schema:name Vertex Pharmaceuticals, 50 Northern Ave, 02210, Boston, MA, USA
246 rdf:type schema:Organization
247 https://www.grid.ac/institutes/grid.422932.c schema:alternateName BioMarin (United States)
248 schema:name BioMarin Pharmaceutical Inc., 770 Lindaro St, 94901, San Rafael, CA, USA
249 rdf:type schema:Organization
250 https://www.grid.ac/institutes/grid.427771.0 schema:alternateName Amicus Therapeutics (United States)
251 schema:name Amicus Therapeutics, Inc., 1 Cedar Brook Drive, 08512, Cranbury, NJ, USA
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.430528.8 schema:alternateName Ultragenyx Pharmaceutical (United States)
254 schema:name Ultragenyx Pharmaceutical, Inc., 60 Leveroni Ct, 94949, Novato, CA, USA
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...